Matrix reloaded: CCN, tenascin and SIBLING group of matricellular proteins in orchestrating cancer hallmark capabilities

详细信息    查看全文

• 作者：Ravi Thakur ; Durga Prasad Mishra ; ^{dpm@cdri.res.in}
• 关键词：ECM ; extracellular matrix ; MCP ; matricellular protein ; SIBLING ; small integrin-binding ligand N-linked glycoproteins ; TSP ; thrombospondin ; SPARC ; secreted protein acidic and rich in cysteine ; TNC ; tenascin-c ; TNR ; tenascin-R ; TNW ; tenascin-W ; TNX ; tenascin-X ; WISP ; Wnt-induced secreted protein ; OPN ; osteopontin ; BSP ; bone sialoprotein ; DMP1 ; dentin matrix protein 1 ; DSPP ; dentine sialophosphoprotein ; MEPE ; matrix extracellular phosphoglycoprotein ; IGFBP ; insulin-like growth factor-binding protei
• 刊名：Pharmacology & Therapeutics
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：168
• 期：Complete
• 页码：61-74
• 全文大小：1461 K
• 卷排序：168

文摘

Matricellular proteins (MCPs) are the non-structural extracellular matrix (ECM) proteins with various regulatory functions. MCPs are critical regulators of ECM homeostasis and are often found dysregulated in various malignancies. They interact with various proteins like ECM structural proteins, integrins, growth factor receptors and growth factors to modulate their availability and activity. Cancer-supporting MCPs are known to induce proliferation, migration and invasion of cancer cells. MCPs also support cancer stem (like) cell growth and induce a drug-resistant state. Apart from their direct effects on cancer cells, they play key roles in angiogenesis, immunomodulation, stromal cell infiltration, stromal proliferation and matrix remodeling. High expression of various MCPs belonging to the tenascin, CCN and SIBLING families is often associated with aggressive tumors and poor patient prognosis. Due to their differential expression and distinct functional role, these MCPs are perceived as attractive therapeutic targets in cancer. Studies on preclinical models have indicated that targeting tumor-supportive MCPs could be a potent avenue for developing anti-cancer therapies. The MCP receptors, like integrins and some associated growth factor receptors, are already being targeted using pharmacological inhibitors and neutralizing antibodies. Neutralizing antibodies against CCNs, tenascins and SIBLINGs have shown promising results in preclinical cancer models, suggesting an opportunity to develop anti-MCP therapies to target cancer. Peptides derived from anti-cancer MCPs could also serve as therapeutic entities. In the present review, in continuation with the expanding horizon of MCP functions and disease association, we focus on (i) their unique domain arrangement, (ii) their association with cancer hallmarks and (iii) available and possible therapeutic interventions.